SEC opens inquiry into Wall Street's SPAC mania — report; A China-based gene therapy player now has $80M more in the bank
The SPAC mania has intensified not just in biotech but throughout the market. And it’s caught so much fire that now the SEC has reportedly opened an inquiry into the matter.
US regulators have reached out to Wall Street banks for information on how they’re managing the risks involved in the blank check mergers, four sources told Reuters. The requests have not risen to the level of a formal demand just yet, but have asked that the banks voluntarily provide the information.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
